



(11) **EP 3 886 820 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**17.05.2023 Bulletin 2023/20**

(45) Date of publication and mention  
of the grant of the patent:  
**12.04.2023 Bulletin 2023/15**

(21) Application number: **19889873.6**

(22) Date of filing: **27.11.2019**

(51) International Patent Classification (IPC):  
**A61K 9/48** <sup>(2006.01)</sup> **A61K 31/451** <sup>(2006.01)</sup>  
**A61K 47/10** <sup>(2017.01)</sup> **A61K 47/14** <sup>(2017.01)</sup>  
**A61K 47/40** <sup>(2006.01)</sup> **A61K 47/44** <sup>(2017.01)</sup>

(52) Cooperative Patent Classification (CPC):  
**A61K 9/4825; A61K 9/4858; A61K 31/451;**  
**A61K 47/10; A61K 47/14; A61K 47/40; A61K 47/44**

(86) International application number:  
**PCT/US2019/063547**

(87) International publication number:  
**WO 2020/112961 (04.06.2020 Gazette 2020/23)**

(54) **CAPSULE FORMULATIONS**  
KAPSELFÖRMULIERUNGEN  
FORMULATIONS DE CAPSULES

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**  
Designated Extension States:  
**BA ME**  
Designated Validation States:  
**KH MA MD TN**

(30) Priority: **30.11.2018 US 201862773848 P**

(43) Date of publication of application:  
**06.10.2021 Bulletin 2021/40**

(60) Divisional application:  
**23160271.5**

(73) Proprietor: **ChemoCentryx, Inc.**  
**Thousand Oaks, CA 91320 (US)**

(72) Inventors:  
• **LELETI, Manmohan Reddy**  
**Dublin, California 94568 (US)**

• **POWERS, Jay P.**  
**Pacifica, California 94044 (US)**

(74) Representative: **J A Kemp LLP**  
**80 Turnmill Street**  
**London EC1M 5QU (GB)**

(56) References cited:  
**US-A1- 2007 298 099 US-A1- 2010 311 753**  
**US-A1- 2017 246 186 US-A1- 2018 179 160**  
**US-A1- 2018 280 530**

• **BEKKER et al.: "Characterization of  
Pharmacologic and Pharmacokinetic Properties  
of CCX168, a Potent and Selective Orally  
Administered Complement 5a Receptor Inhibitor,  
Based on Preclinical Evaluation and Randomized  
Phase 1 Clinical Study", PLOS One, vol. 11, no.  
10, 21 October 2016 (2016-10-21), pages 1-19,  
XP055602780,**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).